Semaphorin‑3A alleviates cardiac hypertrophy by regulating autophagy

Area of Science:

• Cardiology
• Molecular Biology
• Cell Biology

Background:

• Cardiac hypertrophy is an adaptive response that can lead to heart failure.
• Semaphorin-3A (Sema3A) is a neurochemical inhibitor with potential roles in cardiac adaptation.
• Understanding the molecular mechanisms of cardiac hypertrophy is crucial for developing treatments.

Purpose of the Study:

• To investigate the role of Semaphorin-3A (Sema3A) in isoproterenol (ISO)-induced cardiac hypertrophy.
• To elucidate the underlying molecular mechanisms, including autophagy and the Akt/mTOR signaling pathway.

Main Methods:

• Utilized an ISO-induced H9c2 cell model for cardiac hypertrophy.
• Assessed cell surface area, mRNA expression (BNF, β-MHC), and protein levels (LC3, p62, Beclin-1, Akt/mTOR pathway).
• Investigated the effect of rapamycin (autophagy inducer) on Sema3A's protective role.

Main Results:

• ISO treatment significantly increased cardiomyocyte size and hypertrophic markers.
• Sema3A overexpression attenuated ISO-induced hypertrophy and inhibited autophagy.
• Sema3A prevented the decrease in p-Akt, mTOR, and 4EBP1 protein levels induced by ISO.

Conclusions:

• Sema3A exerts a protective effect against ISO-induced cardiac hypertrophy.
• This protection is mediated by the inhibition of autophagy through the Akt/mTOR signaling pathway.
• Sema3A represents a potential therapeutic target for managing cardiac hypertrophy and preventing heart failure.